Greenphire and Ernst & Young Announce Strategic Partnership
News Jul 10, 2013
Greenphire has announced the launch of a strategic partnership with Ernst & Young. The partnership will combine Greenphire’s industry leading eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young’s advisory practice for clients in the pharmaceutical industries.
Within the scope of the partnership, Greenphire’s clients will have access to specialists within Ernst & Young’s global consulting and advisory practice that focuses on global HCP transparency regulatory compliance (e.g. - The US Sunshine Act).
This relationship will increase the strength of Greenphire’s eClinicalGPS technology by giving clients the ability to leverage Ernst & Young’s market leading advisory practice in concert with Greenphire’s market leading payment and data aggregation technology.
Ernst & Young’s advisory practice will further assist Greenphire’s clients to comply with 75+ transparency regulations globally.
Additionally, Ernst & Young’s extensive proprietary research will be routed into a new Greenphire technology solution. The technology, currently in development, will be a first-of-its-kind, web-based SaaS solution to manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all aspects of pharmaceutical operations.
Sam Whitaker, co-founder and CEO of Greenphire, comments: "We are delighted to work with Ernst & Young in what is sure to be an industry-changing partnership. Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant. We are very excited to be able to offer them access to an incredible resource such as Ernst & Young.”
Martin Holyoake, Partner at Ernst & Young said: “We are proud to be working with Greenphire to help ensure that clients successfully navigate the complicated legislative landscape and deliver value. The deep technical knowledge and grounded relationships formed as a result of our long standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight. We look forward to working with Greenphire to bring tangible benefits to our clients.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE